|
gptkbp:instanceOf
|
antiviral drug
protease inhibitor
|
|
gptkbp:administeredBy
|
gptkb:ritonavir
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:ATCCode
|
J05AE09
|
|
gptkbp:brand
|
gptkb:Aptivus
|
|
gptkbp:CASNumber
|
174484-41-4
|
|
gptkbp:category
|
antiretroviral therapy
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugInteraction
|
gptkb:rifampin
gptkb:warfarin
gptkb:St._John's_wort
statins
oral contraceptives
|
|
gptkbp:eliminationHalfLife
|
5.5 hours
|
|
gptkbp:form
|
capsule
oral solution
|
|
gptkbp:hasMolecularFormula
|
C31H33F3N2O5S
|
|
gptkbp:hasSMILES
|
CC(C)C1=CC2=C(C=C1)C(=O)N(C2=O)C3=CC=C(C=C3)C4=CC(=C(C=C4)C(F)(F)F)S(=O)(=O)N5CCCCC5C(=O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tipranavir
|
|
gptkbp:indication
|
HIV-1 strains resistant to other protease inhibitors
|
|
gptkbp:KEGGID
|
D04567
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
99.9%
|
|
gptkbp:PubChem_CID
|
213039
DB00932
CHEMBL1200969
184489
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
hepatotoxicity
|
|
gptkbp:UNII
|
Y5L2157C6B
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:Ritonavir
gptkb:KCNH2
|
|
gptkbp:bfsLayer
|
7
|